The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review
In this narrative review, we analyze pre-registration and post-marketing data concerning
hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of …
hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of …
Long-term drug treatment in multiple sclerosis: safety success and concerns
D Jakimovski, CB Vaughn, S Eckert… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction The portfolio of multiple sclerosis (MS) disease modifying treatments (DMTs)
has significantly expanded over the past two decades. Given the lifelong use of MS …
has significantly expanded over the past two decades. Given the lifelong use of MS …
Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study
Background and Objectives It is not possible to fully establish the safety of a disease-
modifying drug (DMD) for multiple sclerosis (MS) from randomized controlled trials as only …
modifying drug (DMD) for multiple sclerosis (MS) from randomized controlled trials as only …
Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study
E Kingwell, T Zhang, F Zhu, R Walld… - Expert Opinion on …, 2021 - Taylor & Francis
Background Real-world safety data for the oral multiple sclerosis (MS) disease-modifying
therapies (DMTs), dimethyl fumarate (DMF), fingolimod, and teriflunomide are important. We …
therapies (DMTs), dimethyl fumarate (DMF), fingolimod, and teriflunomide are important. We …
Persisting lymphopenia and dimethyl fumarate: A clinical commentary
L Diem, A Chan - Multiple Sclerosis Journal, 2021 - journals.sagepub.com
Severe prolonged lymphopenia as rare side-effect of dimethyl fumarate is mostly reversible.
Caldito et al. report a case of persistent severe lymphopenia over 5 years after …
Caldito et al. report a case of persistent severe lymphopenia over 5 years after …